Juniper Pharma Services invests to strengthen topicals capability

Juniper Pharma Services has reinforced its early stage topical and semi-solids capability by investing in a Becomix homogeniser mixer.

The installation of the new equipment extends the company’s ability to manufacture creams, ointments, and semi-solids to support clinical trials and efficiently deal with more complex formulations.

Used primarily for the production of topical drug products, the Becomix RW30 homogeniser gives the contract development and manufacturing organisation (CDMO) the capability to supply products for Phase III studies.

This addition to our capabilities enables us to develop topical products on a larger scale

Claire Madden-Smith, SVP at Juniper Pharma Services, said: 'This addition to our capabilities enables us to develop topical products on a larger scale and to cater for our clients’ supply needs from first-in-man studies up to and including Phase III, with a commercially replicable process in place.

'We are no stranger to aiding clients with challenging formulations and so the installation of Becomix simply bolsters our ability to support drug development companies that are developing creams, ointments, and semi-solid products, both simple and complex.'

With an integrated electronic batch report system in place, the Becomix reduces operator input and automates the homogenisation process.

Only last week, Juniper announced a substantial investment in its spray drying capabilities. This followed the strengthening of its early stage capsule filling expertise with the expansion of its Xcelodose powder micro-dosing system at the end of last year.